Pouyan, Niloufar http://orcid.org/0000-0003-4606-3528
Younesi Sisi, Farnaz http://orcid.org/0009-0000-1289-1953
Kargar, Alireza http://orcid.org/0000-0001-9582-8879
Scheidegger, Milan http://orcid.org/0000-0003-1313-2208
McIntyre, Roger S. http://orcid.org/0000-0003-4733-2523
Morrow, Jonathan D. http://orcid.org/0000-0002-3530-4544
Article History
Accepted: 16 October 2023
First Online: 24 November 2023
Declarations
:
: NP was employed as the responsible pharmacist at Aracell Zist Darou Pharmaceutical but has received no funding, financial, or infrastructure support for this project from Aracell Zist Darou Pharmaceutical. RSM has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. RSM is a CEO of Braxia Scientific Corp. MS works part-time as CMO for Reconnect Labs, an academic spin-off drug development company that he co-founded in 2021.The rest of the authors have no conflict of interest to declare.
: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
: NP and RSM developed the idea of the RDoC-based framework for the review. NP designed the methodology for screening, data categorization and tabulation. NP, AK, and FYS carried out the screening. NP and FYS prepared the visualizations. FYS and AK performed the risk of bias assessment. JDM provided context and expertise for interpreting the preclinical studies. NP and FYS wrote the paper.NP, FYS, MS, and JDM edited and revised the paper. All authors viewed and approved the final manuscript and had the opportunity to comment on earlier drafts and agree to be accountable for the work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.